HALIFAX, Feb. 5, 2015 /CNW Telbec/ - MedMira Inc.
(MedMira) (TSXV: MIR) reported that the Company's Board of
Directors, comprised of Mr. Hermes
Chan, Dr. Colin MacGillivray,
Mr. Marvyn Robar, Mr. Romano Robusto, and Dr. Michael Sidler, was re-elected at its 2015
Annual General Meeting of Shareholders. Mr. Robar remains as
Chairman of the Board. Shareholders also approved the
appointment of Deloitte LLP as the Company's auditors during the
meeting held January 30, 2015 in
Halifax, N.S.
About MedMira
MedMira is a leading developer and manufacturer of vertical flow
rapid diagnostics. The Company's tests provide hospitals, labs,
clinics and individuals with instant diagnosis for diseases such as
HIV and hepatitis C in just three easy steps. The Company's tests
are sold under the Reveal®, Multiplo™ and Miriad™ brands
in global markets. Based on its patented Rapid Vertical Flow
Technology™, MedMira's rapid HIV test is the only one in the world
to achieve regulatory approvals in Canada, the United
States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova
Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking statements, which
involve risk and uncertainties and reflect the Company's current
expectation regarding future events including statements regarding
possible approval and launch of new products, future growth, and
new business opportunities. Actual events could materially
differ from those projected herein and depend on a number of
factors including, but not limited to, changing market conditions,
successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of
corporate alliances and other risks detailed from time to time in
the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE MedMira Inc.